Medinet Co., Ltd.

Mie Nieda

Manami Isogai

Kazuhiro Kakimi

Mai Tomiyama

Masato Muto

Masashi Takahara

Andrew Nicol

Disclosed are: a method for culture of disease antigen specific CTLs and &#x3b3;&#x3b4;T cells in one culture step conveniently and efficiently; and a pharmaceutical agent and a therapeutic/prophylactic method both of which use a cell produced by the method. Blood is collected and peripheral blood mononuclear cells are separated from the blood. Aminobisphosphonate and a disease antigen are added to the peripheral blood mononuclear cells at the beginning of culture, and the cell culture is carried out for a predetermined period to proliferate/induce disease antigen specific CTLs and &#x3b3;&#x3b4;T cells simultaneously until the numbers of the cells reach values that are effective for the treatment of a disease. The CTLs and the &#x3b3;&#x3b4;T cells thus produced are used for the treatment.

Method for the simultaneous induction of CTL and &#x3b3;&#x3b4;T cell

Activated antigen-presenting cells that can induce immunocytes including disease antigen-specific CD8+ CTLs and/or &#x3b3;&#x3b4; T cells efficiently in vivo and/or in vitro, a medical composition comprising the activated antigen-presenting cells, a treatment and prevention method using the activated antigen-presenting cells, and an induction method of immunocytes including disease antigen-specific CTLs and/or &#x3b3;&#x3b4; T cells induced using the activated antigen-presenting cell, immunocytes induced by the above-noted method, a medical composition comprising the immunocytes, and a treatment and prevention method using the immunocytes are provided. By co-pulsing antigen-presenting cells with bisphosphonate in addition to the pulse with a disease antigen, the ratio of disease antigen-specific CD8+ CTLs and/or &#x3b3;&#x3b4; T cells and the number of the disease antigen-specific CD8+ CTLs and the &#x3b3;&#x3b4; T cells can be increased, compared with the case where the co-pulse with bisphosphonate is not carried out.

Method for activation treatment of antigen-presenting cell

The present invention provides dendritic cells capable of efficiently activating and/or proliferating &#x3b3;&#x3b4; T-cells in vivo and/or in vitro, pharmaceutical compositions comprising said dendritic cells, therapeutic methods and &#x3b3;&#x3b4; T-cell culture methods utilizing said dendritic cells. By pulsing immature dendritic cells derived from peripheral blood monocytes with a bisphosphonate-based bone metabolism improving drug to enable the cells to activate &#x3b3;&#x3b4; T-cells, and cultivating them with a cell subset containing &#x3b3;&#x3b4; T-cells, &#x3b3;&#x3b4; T-cells can be activated and/or proliferated. This allows for easy proliferation of &#x3b3;&#x3b4; T-cells without burdening a patient, leading to practical applications of immune cell therapies that utilize &#x3b3;&#x3b4; T-cells.

Growing community of inventors

Tokyo, Japan

Mie Nieda